LuPSMA-617 and Pembrolizumab in mCRPC - Takeaway - MDSpire
Clinical Guidelines
Feature

LuPSMA-617 and Pembrolizumab in mCRPC

In an Australian phase IB to II study (PRINCE) reported in The Lancet Oncology, Sandhu et al found that the combination of lutetium-177–labeled PSMA-617 (LuPSMA-617) and pembrolizumab was active in pa...

Share

  • 1

    Study published in The Lancet Oncology;

  • 2

    Combination of LuPSMA-617 and pembrolizumab;

  • 3

    37 patients enrolled from 2019 to 2020;

  • 4

    Median follow-up of 30 months;

  • 5

    76% achieved ≥50% PSA reduction;

  • 6

    Manageable toxicity observed;

  • 7

    Results suggest potential durable benefit;

  • 8

    Funded by Victorian Cancer Agency and pharmaceutical companies.

Original Source(s)

LuPSMA-617 and Pembrolizumab in mCRPC

  • by Matthew Stenger

  • April 15, 2026

Related Content

Is Standard of Care Optimal for the Individual Patient?

I am writing this from the hospital waiting room. My father is undergoing an 11-hour surgery to remove his parotid gland and a squamous cell carcinoma that has metastasized from his cheek and invaded ...

From Spectra to Structure: An Interview with Novogaia’s Tess Bevers

Novogaia’s transformer-based model converts untargeted mass spectra into structural predictions for early-stage drug discovery

Mass Spec Roundup: From Masterpieces to Microplastics

Advances in imaging, AI, and single-cell analysis reveal hidden chemistry in art, biology, and the environment

  • April 15, 2026

  • 6 min